2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Hugel: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics" - Frown Lines | Phase 2 | Completed | Croma-Pharma GmbH | 208 | 2020-06-24 | 2025-03-18 |
| Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy Botulinum Toxin Type A Injection (Botulax®) 24Units, Botulinum Toxin Type A Injection (Botulax®) 48Units, Botulinum Toxin Type A Injection (Botulax®) 72Units - Benign Masseteric Hypertrophy | Phase 2 | Completed | Hugel | 80 | 2020-05-27 | 2021-11-16 |
| the Hypertrophic Scar Prevention of BMT101. BMT101 - Hypertrophic Scar | Phase 2 | Terminated | Hugel | 20 | 2019-08-21 | 2023-05-24 |
Cicatrix (1) · Cicatrix, Hypertrophic (1)
Botulinum Toxins, Type A (1) · Saline Solution (1)
South Korea (2) · Austria (1) · Canada (1) · United States (1)